Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients

Determining the optimal dose of warfarin for frail elderly patients is a challenging task because of the low dose requirements in such patients, the wide interindividual variability of response, and the associated risk of bleeding. The objective of this study was to address the influence of 13 commo...

Full description

Saved in:
Bibliographic Details
Published inClinical pharmacology and therapeutics Vol. 87; no. 1; p. 57
Main Authors Pautas, E, Moreau, C, Gouin-Thibault, I, Golmard, J-L, Mahé, I, Legendre, C, Taillandier-Hériche, E, Durand-Gasselin, B, Houllier, A-M, Verrier, P, Beaune, P, Loriot, M-A, Siguret, V
Format Journal Article
LanguageEnglish
Published United States 01.01.2010
Subjects
Online AccessGet more information
ISSN1532-6535
DOI10.1038/clpt.2009.178

Cover

Loading…
Abstract Determining the optimal dose of warfarin for frail elderly patients is a challenging task because of the low dose requirements in such patients, the wide interindividual variability of response, and the associated risk of bleeding. The objective of this study was to address the influence of 13 common variations in eight genes on the maintenance dose of warfarin in a cohort of frail elderly inpatients. For our study, we enrolled 300 Caucasian subjects who were hospital inpatients, with a mean age of 86.7 +/- 6 years. In addition to age, genetic variants of VKORC1, CYP2C9, CYP4F2, and EPHX1 were found to be significant predictor variables for the maintenance dose of warfarin, explaining 26.6% of dose variability. Among 132 patients in whom warfarin therapy was initiated with the same low-dose regimen, we studied the relative influences of genetic and nongenetic factors. The time to first international normalized ratio (INR) > or =2 was influenced by VKORC1 and CYP2C9 genotypes (P = 0.0003 and P = 0.0016, respectively); individuals with multiple variant alleles were at highest risk for overanticoagulation (INR >4) (odds ratio, 12.8; 95% confidence interval, 2.73-60.0). In this special population of frail elderly patients with multiple comorbidities and polypharmacy, we demonstrated the main impact of genetic factors on warfarin response.
AbstractList Determining the optimal dose of warfarin for frail elderly patients is a challenging task because of the low dose requirements in such patients, the wide interindividual variability of response, and the associated risk of bleeding. The objective of this study was to address the influence of 13 common variations in eight genes on the maintenance dose of warfarin in a cohort of frail elderly inpatients. For our study, we enrolled 300 Caucasian subjects who were hospital inpatients, with a mean age of 86.7 +/- 6 years. In addition to age, genetic variants of VKORC1, CYP2C9, CYP4F2, and EPHX1 were found to be significant predictor variables for the maintenance dose of warfarin, explaining 26.6% of dose variability. Among 132 patients in whom warfarin therapy was initiated with the same low-dose regimen, we studied the relative influences of genetic and nongenetic factors. The time to first international normalized ratio (INR) > or =2 was influenced by VKORC1 and CYP2C9 genotypes (P = 0.0003 and P = 0.0016, respectively); individuals with multiple variant alleles were at highest risk for overanticoagulation (INR >4) (odds ratio, 12.8; 95% confidence interval, 2.73-60.0). In this special population of frail elderly patients with multiple comorbidities and polypharmacy, we demonstrated the main impact of genetic factors on warfarin response.
Author Gouin-Thibault, I
Durand-Gasselin, B
Moreau, C
Taillandier-Hériche, E
Pautas, E
Siguret, V
Mahé, I
Legendre, C
Golmard, J-L
Houllier, A-M
Beaune, P
Verrier, P
Loriot, M-A
Author_xml – sequence: 1
  givenname: E
  surname: Pautas
  fullname: Pautas, E
  organization: Université Paris Descartes, Paris, France
– sequence: 2
  givenname: C
  surname: Moreau
  fullname: Moreau, C
– sequence: 3
  givenname: I
  surname: Gouin-Thibault
  fullname: Gouin-Thibault, I
– sequence: 4
  givenname: J-L
  surname: Golmard
  fullname: Golmard, J-L
– sequence: 5
  givenname: I
  surname: Mahé
  fullname: Mahé, I
– sequence: 6
  givenname: C
  surname: Legendre
  fullname: Legendre, C
– sequence: 7
  givenname: E
  surname: Taillandier-Hériche
  fullname: Taillandier-Hériche, E
– sequence: 8
  givenname: B
  surname: Durand-Gasselin
  fullname: Durand-Gasselin, B
– sequence: 9
  givenname: A-M
  surname: Houllier
  fullname: Houllier, A-M
– sequence: 10
  givenname: P
  surname: Verrier
  fullname: Verrier, P
– sequence: 11
  givenname: P
  surname: Beaune
  fullname: Beaune, P
– sequence: 12
  givenname: M-A
  surname: Loriot
  fullname: Loriot, M-A
– sequence: 13
  givenname: V
  surname: Siguret
  fullname: Siguret, V
BackLink https://www.ncbi.nlm.nih.gov/pubmed/19794411$$D View this record in MEDLINE/PubMed
BookMark eNo1kEtLAzEUhYMo9qFLt5KlQqfmNU2ylKEPsdAiRXRVMskNjEynQzJWuvaPm6Kuzj0fnAvnDNB5s28AoRtKxpRw9WDrthszQvSYSnWG-jTnLJvkPO-hQYwfhBChlbpEPaqlFoLSPvqeQwNdZbE3ttuHiO9en1cvBR3h4n3NCj3C0_XiLVnTuBMSM3aPTQDcBnDVKYIPJlSmrCFin9yXCT6BBgeI7b6JgNN9gHDEUDsI9XGEfTBVnXBrugqaLl6hC2_qCNd_OkSb2XRTLLLlav5UPC4zKzhXmZcCnJTWEKkcZUAk584SaonXRhFVeqlyzVPdiTClAuUnKcKVcKAFI2yIbn_ftp_lDty2DdXOhOP2fwz2A6hdX1E
CitedBy_id crossref_primary_10_1177_1076029616654264
crossref_primary_10_2217_pgs_2020_0054
crossref_primary_10_1016_j_etap_2015_05_008
crossref_primary_10_1007_s40262_023_01258_y
crossref_primary_10_1186_s40246_018_0157_3
crossref_primary_10_1016_S1734_1140_13_70977_0
crossref_primary_10_1007_s00228_018_2528_z
crossref_primary_10_2217_pgs_10_49
crossref_primary_10_1016_j_jacc_2010_08_643
crossref_primary_10_2217_pgs_11_156
crossref_primary_10_1016_j_thromres_2011_11_043
crossref_primary_10_1007_s40291_013_0055_2
crossref_primary_10_1517_13543784_2012_707194
crossref_primary_10_1007_s11096_010_9448_z
crossref_primary_10_1007_s40266_024_01117_w
crossref_primary_10_1093_eurheartj_ehr239
crossref_primary_10_1007_s00228_013_1581_x
crossref_primary_10_3389_fphar_2017_00323
crossref_primary_10_1111_j_1365_2125_2010_03709_x
crossref_primary_10_2165_10061610_000000000_00000
crossref_primary_10_1007_s11239_012_0725_7
crossref_primary_10_1186_1749_8090_7_97
crossref_primary_10_1586_17512433_2013_842125
crossref_primary_10_1592_phco_31_12_1192
crossref_primary_10_1007_s00228_017_2265_8
crossref_primary_10_1161_CIRCULATIONAHA_109_914820
crossref_primary_10_2217_pgs_11_164
crossref_primary_10_1038_s41397_021_00224_w
crossref_primary_10_1038_jhg_2010_73
crossref_primary_10_1016_j_clinbiochem_2012_01_002
crossref_primary_10_1309_AJCPAO82OTNPUBLW
crossref_primary_10_1111_j_1365_2710_2011_01317_x
crossref_primary_10_1007_s00228_012_1356_9
crossref_primary_10_2217_pgs_2019_0139
crossref_primary_10_2217_pgs_10_162
crossref_primary_10_2217_pgs_12_65
crossref_primary_10_1160_TH13_07_0555
crossref_primary_10_1155_2015_564149
crossref_primary_10_1007_s00204_013_1013_9
crossref_primary_10_1097_FPC_0000000000000244
crossref_primary_10_1182_blood_2011_07_365502
crossref_primary_10_1007_s11096_011_9486_1
crossref_primary_10_3389_fphar_2023_1105702
crossref_primary_10_1016_j_genrep_2020_100769
crossref_primary_10_3389_fphar_2020_01014
crossref_primary_10_1016_j_thromres_2018_05_002
crossref_primary_10_1002_pbc_24932
crossref_primary_10_1016_j_clinthera_2012_02_009
crossref_primary_10_1038_clpt_2011_179
crossref_primary_10_3390_jpm10030117
crossref_primary_10_1002_cpt_1323
crossref_primary_10_1371_journal_pone_0105250
crossref_primary_10_1002_phar_1717
crossref_primary_10_1007_s11834_010_0011_Y
crossref_primary_10_1093_hmg_ddq389
crossref_primary_10_1111_j_1365_2710_2012_01340_x
crossref_primary_10_1016_S2211_9698_11_71437_6
crossref_primary_10_2217_pgs_12_171
crossref_primary_10_1111_j_1365_2125_2012_04354_x
crossref_primary_10_1016_j_jamda_2010_12_006
crossref_primary_10_1016_j_pharep_2013_09_006
crossref_primary_10_2217_fca_10_6
crossref_primary_10_1080_21551197_2012_729902
crossref_primary_10_1038_clpt_2012_184
crossref_primary_10_1111_jth_12105
crossref_primary_10_3390_ph3123543
crossref_primary_10_4155_fsoa_2017_0112
crossref_primary_10_1093_labmed_lmx072
crossref_primary_10_1111_j_1365_2125_2011_04095_x
crossref_primary_10_1007_s00228_012_1448_6
crossref_primary_10_1097_HCO_0b013e32835f0bbc
crossref_primary_10_1097_FTD_0b013e318256a77c
crossref_primary_10_1111_j_1365_2125_2011_03942_x
crossref_primary_10_1111_jphp_12084
crossref_primary_10_1016_j_revmed_2009_07_014
crossref_primary_10_1007_s43440_023_00476_2
crossref_primary_10_2217_pme_14_80
crossref_primary_10_1038_clpt_2011_31
crossref_primary_10_1038_clpt_2011_76
crossref_primary_10_1111_j_1538_7836_2011_04213_x
crossref_primary_10_2217_pgs_2018_0146
crossref_primary_10_2217_pgs_2018_0143
crossref_primary_10_1038_clpt_2009_307
crossref_primary_10_1007_s00228_010_0950_y
crossref_primary_10_1007_s40266_013_0101_0
crossref_primary_10_1016_j_cca_2010_04_014
crossref_primary_10_1016_j_gene_2017_10_049
crossref_primary_10_1016_j_thromres_2013_03_019
crossref_primary_10_1007_s40256_015_0126_3
crossref_primary_10_1007_BF03319099
crossref_primary_10_1007_s11033_014_3617_4
crossref_primary_10_1185_03007995_2014_912982
crossref_primary_10_1097_MD_0000000000005658
crossref_primary_10_1109_JBHI_2014_2336974
crossref_primary_10_1111_bcpt_12024
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1038/clpt.2009.178
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1532-6535
ExternalDocumentID 19794411
Genre Journal Article
Comparative Study
GroupedDBID ---
--K
-Q-
.55
.GJ
0R~
1B1
1CY
1OB
1OC
29B
33P
354
36B
39C
3O-
4.4
52O
53G
5GY
5RE
6J9
70F
8F7
AAESR
AAHHS
AAHQN
AAIPD
AAKAS
AAMNL
AANHP
AANLZ
AAONW
AAQOH
AAQQT
AAWTL
AAYCA
AAYOK
AAZKR
ABCUV
ABJNI
ABLJU
ABQWH
ACBNA
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACGOF
ACPOU
ACRPL
ACXQS
ACYXJ
ADBBV
ADBTR
ADKYN
ADNMO
ADXAS
ADZCM
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AENEX
AEQDE
AEUYR
AFBPY
AFFNX
AFFPM
AGHNM
AHBTC
AI.
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMYDB
ASPBG
AVWKF
AZFZN
AZVAB
BDRZF
BFHJK
BMXJE
BRXPI
C45
CAG
CGR
COF
CS3
CUY
CVF
DCZOG
DPXWK
DU5
EBS
ECM
EE.
EIF
EJD
EMOBN
F5P
GODZA
GWYGA
HGLYW
IH2
IHE
J5H
L7B
LATKE
LEEKS
LITHE
LOXES
LSO
LUTES
LYRES
M41
MEWTI
N4W
N9A
NPM
NQ-
O9-
OPC
OVD
P2P
P2W
PALCI
RIG
RIWAO
RJQFR
RNTTT
ROL
RPZ
SAMSI
SEW
SJN
SUPJJ
TEORI
TWZ
UHS
VH1
WBKPD
WH7
WOHZO
WXSBR
X7M
Y6R
YCJ
YFH
YOC
YXB
ZGI
ZXP
ZZTAW
ID FETCH-LOGICAL-c4338-f74ed77ca078d12e0733dc01c0f9a808bf7859353564ab8e8f6f74384de94202
IngestDate Thu Apr 03 07:05:46 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c4338-f74ed77ca078d12e0733dc01c0f9a808bf7859353564ab8e8f6f74384de94202
PMID 19794411
ParticipantIDs pubmed_primary_19794411
PublicationCentury 2000
PublicationDate January 2010
PublicationDateYYYYMMDD 2010-01-01
PublicationDate_xml – month: 01
  year: 2010
  text: January 2010
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Clinical pharmacology and therapeutics
PublicationTitleAlternate Clin Pharmacol Ther
PublicationYear 2010
References 21593757 - Clin Pharmacol Ther. 2011 Jun;89(6):791; author reply 792
References_xml – reference: 21593757 - Clin Pharmacol Ther. 2011 Jun;89(6):791; author reply 792
SSID ssj0004988
Score 2.3406677
Snippet Determining the optimal dose of warfarin for frail elderly patients is a challenging task because of the low dose requirements in such patients, the wide...
SourceID pubmed
SourceType Index Database
StartPage 57
SubjectTerms Age Factors
Aged
Aged, 80 and over
Aryl Hydrocarbon Hydroxylases - genetics
Cohort Studies
Cytochrome P-450 CYP2C9
Cytochrome P-450 Enzyme System - genetics
Cytochrome P450 Family 4
Dose-Response Relationship, Drug
Epoxide Hydrolases - genetics
Female
Frail Elderly
Genetic Testing
Genetic Variation - drug effects
Genetic Variation - genetics
Hospitalization - trends
Humans
International Normalized Ratio - trends
Male
Mixed Function Oxygenases - genetics
Polymorphism, Genetic - genetics
Prospective Studies
Risk Factors
Vitamin K Epoxide Reductases
Warfarin - pharmacology
Title Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients
URI https://www.ncbi.nlm.nih.gov/pubmed/19794411
Volume 87
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELa6cOGCeD8W0BzQCtQEktR5-IgqdquFhQgFVE4rJ7FFpW4bdVtQufKb-H_M2HGbLg8BlyhyFCvy92k8nsx8w9jjStWDMFGBr3gW-FzFaAdrFfvkXAiZCRkKKk4-eZOM3vPjcTzu9b53spZWy_JZ9fWXdSX_gyqOIa5UJfsPyG4mxQG8R3zxigjj9a8wJs1oElx1TXPQW_zw6u27YWjCnx_zaCiMrctH49ClaeIwP4woGEA5X82CftTgy_3PeGimMiqjz9D_IhcaB6jWxeTQGmkRXJ91X1Fbb9ueWi_khCQ7Wm3W866jO3QVl81WG3vt0jVdxdfGn88lpYbvFEaczNGdXe3EcY_mq8nMLz5NSrmaLndCvkfz6Zm0WfrH_utuKMNkxLlQhnLmN_KT2AqYOPvcbshdHlpja5Wtf9oDrOJ7NW2WVo40tD2COnxozgwhQoHGiFtb_-enFyS53aM9toeHE-q2SiEiV4wrsqwVc8Uveb7zHUai1r574Rhj3JniGrvankPghSXVddZTsxvsILdgrT0oOih5cAB5B8ab7FvLPGiZB08s7zywrPPAcM4DBBws454C8g02fIMN3wD5Bo5v4PgGeE98g5ZvHhi2wZZtt1hx-LIYjvy2nYdf8QFuqzrlqk7TSqJXWoeRonahdRWEVaDRKgRZqVMS30P0Ey7LTGU6wVcGGa-V4FEQ3WaXZvOZussAjzg6LXGWIKt4IkUZ64Dm1QLdXxlE99gdu7anjZVsOXWrfv-3T_bZlS0lH7DLGm2EeogO57J8ZAD-AdD9fY8
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Genetic+factors+%28VKORC1%2C+CYP2C9%2C+EPHX1%2C+and+CYP4F2%29+are+predictor+variables+for+warfarin+response+in+very+elderly%2C+frail+inpatients&rft.jtitle=Clinical+pharmacology+and+therapeutics&rft.au=Pautas%2C+E&rft.au=Moreau%2C+C&rft.au=Gouin-Thibault%2C+I&rft.au=Golmard%2C+J-L&rft.date=2010-01-01&rft.eissn=1532-6535&rft.volume=87&rft.issue=1&rft.spage=57&rft_id=info:doi/10.1038%2Fclpt.2009.178&rft_id=info%3Apmid%2F19794411&rft_id=info%3Apmid%2F19794411&rft.externalDocID=19794411